Syngenta invests in Avidex

06-Jan-2006

Avidex announced that Syngenta AG has made an investment of £5 million in Avidex in exchange for a minority equity stake. Avidex announced that Dr Ian Kimber of Syngenta will join the Board of Directors of Avidex effective January 1, 2006.

Dr Ian Kimber is a Syngenta Principal Fellow with special interests in, and responsibilities for, immunology, allergy and inflammation. He is based at the Syngenta Central Toxicology Laboratory in Cheshire UK and has served Syngenta, and its legacy companies, for more than 20 years in a variety of scientific and management positions.

His current research interests include all aspects of allergic sensitisation and allergic disease, the biology of dendritic cells and the regulation of cutaneous immune function. Dr Kimber has published over 450 research papers, review articles and book chapters and sits on the editorial boards of immunology, pathology, dermatology and toxicology journals. In addition he serves on a variety of national and international scientific advisory boards and expert committees.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances